# Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics

> **NCT02821416** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 46 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Benralizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02821416
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-11
- **Primary completion:** 2019-10-22
- **Final completion:** 2019-10-22
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821416, "Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02821416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*